Determination of preclinical safety of oil obtained from<i>Pachira aquatica</i>Aublet (Malvaceae) seeds: histopathological, biochemical, hematological, and genetic toxicity studies in rats

Marcelino, Jhony Moreira; Boas, Gustavo Roberto Villas; Cunha, Mila Silva; Júnior, Ramão Deus; Castro, Luis Henrique Almeida; Araújo, Flávio Henrique Souza de; Traesel, Giseli Karenina; Santos, Ariany Carvalho dos; Souza, Roosevelt Isaías Carvalho; Paes, Marina Meirelles; Gubert, Priscila; Guterres, Zaira da Rosa; Lima, Fernando Freitas de; Silva, Tania; Silva, Rogério César; Cardoso, Cláudia Andréa Lima; Sanjinez-Argandoña, Eliana Janet; Macorini, Luís Fernando Benitez; Oesterreich, Silvia Aparecida

doi:10.1080/01480545.2020.1845713

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If API crosses the epithelial barrier, a battery of six assays of safety and activity that cannot be studied in humans should be included: mutagenicity, carcinogenicity, one (and two)‐generation reproduction toxicity, neurotoxicity, embryotoxicity, and genetic studies (Lard‐Whiteford et al, 2004). Mutagenicity and genetic studies evaluate chromosomal and structural DNA changes, such as duplications, insertions, or translocations (da Silva Dantas et al, 2020; Nakamura et al, 2020; Prado‐Ochoa et al, 2020), and identify gene mutations (Gao et al, 2020; Marcelino et al, 2020; Park et al, 2020). Carcinogenicity studies evaluate tumors' development after 18 in mice or hamsters or 24 months in rats (Dekant et al, 2020; Prado‐Ochoa et al, 2020; Saleh et al, 2020).…”

Section: In Vivo Preclinical Studiesmentioning

confidence: 99%

Baseline and time‐updated factors in preclinical development of anionic dendrimers as successful anti‐HIV‐1 vaginal microbicides

Rodriguez-Izquierdo

Sepúlveda‐Crespo

Lasso³

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Although a wide variety of topical microbicides provide promising in vitro and in vivo efficacy, most of them failed to prevent sexual transmission of human immunodeficiency virus type 1 (HIV-1) in human clinical trials. In vitro, ex vivo, and in vivo models must be optimized, considering the knowledge acquired from unsuccessful and successful clinical trials to improve the current gaps and the preclinical development protocols. To date, dendrimers are the only nanotool that has advanced to human clinical trials as topical microbicides to prevent HIV-1 transmission. This fact demonstrates the importance and the potential of these molecules as microbicides. Polyanionic dendrimers

show abstract